1. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
- Author
-
Bravo, Marta Santos, Plault, Nicolas, Palomino, Sonsoles Sánchez, Gutierrez, María Mar Mosquera, Avilés, Francesc Fernández, Lledo, María Suarez, Fernández, Nuria Sabé, Rovira, Montserrat, Alain, Sophie, Maeso, M Ángeles Marcos, Santos Bravo, Marta, Sánchez Palomino, Sonsoles, Mosquera Gutierrez, María Mar, Fernández Avilés, Francesc, Suarez Lledo, María, Sabé Fernández, Nuria, and Marcos Maeso, M Ángeles
- Subjects
HEMATOPOIETIC stem cells ,TRANSPLANTATION of organs, tissues, etc. ,PHENOTYPES ,CYTOMEGALOVIRUS diseases ,GENOTYPES ,PAROXYSMAL hemoglobinuria ,CHRONIC hepatitis B ,GANCICLOVIR ,CYTOMEGALOVIRUSES ,RESEARCH ,GENETIC mutation ,HETEROCYCLIC compounds ,NUCLEOSIDES ,RESEARCH methodology ,PATIENTS ,KIDNEY transplantation ,ANTIVIRAL agents ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,TRANSFERASES ,RESEARCH funding ,DRUG resistance in microorganisms ,HEMATOPOIETIC stem cell transplantation ,PHARMACODYNAMICS - Abstract
Two transplant recipients (1 kidney and 1 hematopoietic stem cell) received maribavir (MBV) after cytomegalovirus (CMV) infection clinically resistant to standard therapy. Both patients achieved CMV DNA clearance within 30 and 18 days; however, the UL97 C480F variant emerged, causing recurrent CMV infection after a cumulative 2 months of MBV and 15 or 4 weeks of ganciclovir treatment, respectively. C480F was not detected under ganciclovir before MBV treatment. Recombinant phenotyping showed that C480F conferred the highest level of MBV resistance and ganciclovir cross-resistance, with impaired viral growth. Clinical follow-up and genotypic and phenotypic studies are essential for the assessment and optimization of patients with suspected MBV resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF